Revolution Medicines' Daily Pill Daraxonrasib Nearly Doubles Survival in Metastatic Pancreatic Cancer, Cutting Risk of Death by 60 Percent
Phase 3 RASolute 302 data show the oral RAS inhibitor extending median overall survival to 13.2 months versus 6.7 months on chemotherapy, sending Revolution Medicines shares up nearly 40 percent.
Overview
Revolution Medicines reported on April 13 that its experimental oral RAS inhibitor daraxonrasib succeeded in the pivotal Phase 3 RASolute 302 trial, nearly doubling overall survival in patients with previously treated metastatic pancreatic cancer compared with chemotherapy. Patients on the daily pill lived a median of 13.2 months versus 6.7 months for those on chemotherapy, a finding that equates to roughly a 60 percent reduction in the risk of death, according to BioPharma Dive.
The readout is one of the most striking results reported in metastatic pancreatic cancer in years. Revolution Medicines’ shares surged on the news, with the company’s CEO Mark Goldsmith telling reporters the drug had hit every primary and secondary endpoint in an interim analysis that the trial’s independent monitors declared final, as reported by CNBC.
What We Know
- Trial design. RASolute 302 enrolled a broad population of previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC), randomizing them to daraxonrasib taken orally once daily or to investigator’s choice chemotherapy. The co-primary endpoints were progression-free survival and overall survival in patients whose tumors carried a RAS G12 mutation, BioPharma Dive reported.
- Survival benefit. In the overall trial population, daraxonrasib extended median overall survival to 13.2 months versus 6.7 months on chemotherapy — nearly double — according to CNBC. BioPharma Dive characterized the result as a roughly 60 percent reduction in the risk of death.
- Safety. The drug was generally well tolerated with a manageable safety profile and no new safety signals, CNBC reported.
- Expert reaction. Benjamin Weinberg, an associate professor at Georgetown University, called the results “very impressive” in commentary provided to STAT. An RBC Capital Markets analyst went further, describing the data as a “game-changer” and “among the most important advancements in the broader field of treating pancreatic cancer,” BioPharma Dive reported.
- Regulatory path. Revolution Medicines said it plans to file for FDA approval using a Commissioner’s National Priority Voucher, which can shorten the standard review timeline, and will present the full dataset at the 2026 American Society of Clinical Oncology Annual Meeting, per CNBC.
- Market reaction and M&A context. Revolution Medicines had been rumored earlier this year as a possible acquisition target for Merck & Co, which has since made a separate bid for Terns Pharmaceuticals, BioPharma Dive reported.
Disease Context
Metastatic pancreatic cancer remains one of the most lethal common malignancies. Standard second-line care has long centered on intravenous cytotoxic chemotherapy regimens that deliver only modest survival gains, and pancreatic cancer is described as “especially deadly and intractable,” STAT noted. A once-daily oral therapy that roughly doubles median survival — if confirmed and approved — would represent a substantive shift in a disease where incremental improvements have typically been measured in weeks.
RAS mutations drive a large share of pancreatic, lung, and colorectal cancers but were long considered “undruggable.” Daraxonrasib is part of a newer class of RAS inhibitors designed to hit several mutant RAS variants at once rather than a single allele such as KRAS G12C, and its success in a trial that enrolled a broad pancreatic population — including patients without a detected RAS mutation — is why analysts are describing the readout as a potential category-defining moment, BioPharma Dive reported.
What We Don’t Know
Revolution Medicines did not disclose the total number of patients enrolled in RASolute 302 or the precise progression-free survival and objective response figures in its topline announcement; those details are expected at the ASCO presentation later this year, CNBC reported. The durability of responses, performance across specific RAS variants, and how daraxonrasib will fit alongside first-line combinations also remain open questions, and the ultimate FDA review timing will depend on when the New Drug Application is filed and how the agency applies the National Priority Voucher in practice.